Total medical devices industry venture financing deals in July 2020 worth $1.8bn were announced globally, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked an increase of 78.9% over the previous month and a rise of 61.2% when compared with the last 12-month average, which stood at $1.12bn.
Comparing deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $1.21bn. At the country level, the US topped the list in terms of deal value at $1.2bn.
In terms of volumes, Asia-Pacific emerged as the top region for medical devices industry venture financing deals globally, followed by North America and then Europe.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
The top country in terms of venture financing deals activity in July 2020 was the US with 51 deals, followed by China with 27 and Australia with 21.
In 2020, as of the end of July 2020, medical devices venture financing deals worth $9.63bn were announced globally, marking an increase of 59.5% year on year.
Medical devices industry venture financing deals in July 2020: Top deals
The top five medical devices industry venture financing deals accounted for 36.7% of the overall value during July 2020.
The combined value of the top five medical devices venture financing deals stood at $661m, against the overall value of $1.8bn recorded for the month.
The top five medical devices industry deals of July 2020 tracked by GlobalData were:
1) Bain Capital Life Sciences, Brown Advisory, Casdin Capital, Driehaus Capital Management, Intermountain Ventures, Janus Henderson Investors, Lux Capital, Moore Strategic Ventures, Perceptive Advisors, Rock Springs Capital Management, Sands Capital Management, Section 32 and T Rowe Price Associates’ $257m venture financing of Thrive Earlier Detection
2) The $137m venture financing of Preventice by Boston Scientific, Merck Global Health Innovation Fund, Novo Holdings, Samsung Catalyst Fund and Vivo Capital
3) BlackRock, Connecticut Innovations, Decheng Capital, Deerfield ManagementLP, Moore Strategic Ventures, Oak HC/FT Partners, Section 32 and The Blackstone Group’s $121m venture financing of Mount Sinai Genomics
4) The $75m venture financing of Doctor On Demand by General Atlantic
5) Clal Biotechnology Industries, Koch Disruptive Technologies, Longliv Ventures and OurCrowd Management’s venture financing of Sight Diagnostics for $71m.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.